The Canada-Sweden Clurithnmzycin-Pneumonia Study C m p
The efficacy and safety of orally administered clarithromycin and erythromycin in the treatment of communityacquired pneumonia were assessed in a multicenter, doubleblind, randomized study. Two hundred sixtyeight patients were randomized to receive either clarithromycin, 250 mg twice a day, or erythromycin stearate, 500 mg 4 times a day, for 7 to 14 days. Efficacy was evaluable in 173 patients (92 for clarithromycin, 81 for erythromycin). No statistically significant difference in clinical success rate (cure or improvement) was observed between the two groups (clarithromycin, 97 percent; erythromycin, 96 percent). Both groups had identical radiologic response (97 percent with resolution or improvement). Similarly, no statistically significant difference in bacteriologic response toward the target pathogens was observed among evaluable patients (clarithromycin, 23/26; erythromycin, 17/17; p value = M acrolide antibiotics have a broad spectrum of activities against the common pathogens for community-acquired pneumonia.' These include Streptococcus pneumoniae, Henwphilus inj?uenzae, and Moraxella catarrhalis, as well as those leading to atypical pneumonia, such as M y c o p l m pneumoniae, Chlamydia pneumoniae (TWAR), and Legionella pneumophilia. Clarithromycin is a new generation of macrolide. Its in uitro activity against these pathogens is, in general, more potent than e r y t h r o m y~i n .~~ For instance, the minimal inhibitory concentration (MICSO) of clarithromycin against S pneumoniae is twofold less than that of erythromycin (0.015 m g L vs 0.03 mgL).
Pharmacokinetic studies showed that clarithromycin, in combination with its active 14-hydroxy metabolite, has a longer half-life and higher plasma level 0.287). Clinical response toward Mycoplasma and Chlamydia pneumonia was comparable between the two groups (clarithromycin, 15/16; erythromycin, 10/11). However, patients receiving erythromycin had a twofold higher incidence of adverse events, mostly related to the gastrointestinal system, and were five times more likely to withdraw from therapy because of drug-related adverse events. These results show that clarithromycin is as effective as erythromycin in the outpatient treatment of community-acquired pneumonia. Furthermore, the lower incidence of adverse events associated with clarithromycin indicates that it is more acceptable to patients and, therefore, can enhance compliance.
(Chest 1993; 103:697-701) i = intermediate; MIC = minimal inhibitory concentration; r = resistant; s = susceptible than erythromycin at an equivalent dose.5 In addition, clarithromycin has better pulmonary tissue penetration, with a 5:l ratio of lung tissue-to-plasma concentrationS2 These data suggest that clarithromycin can be as effective as erythromycin, even at a lower dose and less frequent interval. The purpose of this study is to compare the clinical efficacy and safety of clarithromycin with erythromycin in the treatment of community-acquired pneumonia using a randomized, double-blind controlled study design.
The study was cnnducted between January 1989 and June 1990. All centers obtained approval from respective ethics committee prior to initiation of the study.
Patients above 12 years of age and with a diagnosis of cnmm~~nity-acquired pneumonia were eligible for the study. Diagnosis of pneumonia was based o n pretreatment chest radiograph (CXR) demonstrating a new infiltrate(s) cnnsistent with pneumonia; n positive bacterial culture of b n ) n c h o m o n a r y secretions before treatment or a history and clinical findings cnnsistent with a diagnosis of bacterial or atypical pneumonia to be confirmed subsequently by positive culture or serologic results.
Exclusion criteria included history of hypersensitivity reaction to macn~lide antibiotics, severe renal dysfunction (serum creatinine 22.0 mgldl), hepatic dysfunction with transaminase level twice the
Ilpper limit of normal. pneumonia sr~spected of Legionella or s t a p h y l~~w c a l origin. active tl~hercl~losis or h~n g tllmor. rlse of systemic antihiotics within 3 days before treatment of cnnc~~rrent use of other systemic antihiotics, and pregnant or Iiictating women. Informed consent wts obtained from ill1 patients.
1)mg Adrnini.vtmtion and Blinding fhrrdtrms
At each centrr, patients wrre randomized in :I 1:l ratio to receive either oral clarithromycin. 250 mg every I2 h, or erythromycin stearate. S K I mg every 6 h for 7 to 14 days. For blinding prlrpnses. all patients received 2 prepackaged tablets every 6 h. Patirnts assigned to the clarithromycin group receivrd 1 clarithromycin tablet and 1 erythromycin placehn taldet every 12 h. alternating with 2 placehn tahlrts every 12 h. Patients receiving enthromycin t m k 1 erythro~nycin tahlet and I clarithromycin placeho tahlet every 6 h. The randomiz~tion was hlindrd to h t h the investigators and the patients.
At entry, a cnmplete history, physical examination. and a (:XR were performed on each patient. Symptoms of ro~lgh and dyspnra urerP graded as ahsent, mild, mcderate, or severe. The presence of fever, cyanosis, vales. and rhonchi were noted. A specimen of l,ronchopnln~onary secretions, if available. was obtained 48 h hefnre initiation of therapy. In addition, cnmplement fixation tests C)r hf prwumoniw and C' p n e u m i a v were performed. Other laboratory investigations incl~lded mmplete hematologic and cnagulation profiles, senlm electrolytes, creatininr and urine analysis. liver function tests, and two sets of hlood c~~l t r~r e s .
A ~~r i n e pregnitncy test was perfornied on women of child-hearing age.
Patients r e t~~r n e d for assessment of symptoms and signs. adverse effects, and mn~pliance (tablet cr~llnts) hetween day 5 and day 7. Posttreatment evalr~;~tions were performed within 48 h and 4 to 6 weeks after the last dose. At rach of the ; t h v e visits, assessment of signs and symptoms. mmpliance, and adverse effects were performed. In addition, a specimen of hronchol)~ilmonary secretions was ohtailled and all haselinr Ii~hnratory tests were repei~ted. At thr last visit. r~,mplement fixation tests for Af pwumr)nicrp and C:
pwumo~tinu were repeated and a (:XR was performed. A for~rfold i~~c , r e i~~( -in the serologic titers fnr Ad p w u w ) t~i a~, end (: pnc~rrr~loninc~ \r :IS cwnsidered positive cr)nversion. It1 ~.itm srlsceptihility st~ldies to hnth clarithromycin and erythron~\-c.in were performed on ;III positive pretreatmrnt c~~ltures.
11\ing the disk inhihition zone techniqr~e." It wits graded as sllsceptihle (5). intermediate (i), or resistant (r) depending on thr sizr of the zone ( e l 8 mm. i = 14-17 mm. r C l 3 mm). Even t h o~~g h the 14-hydroxy metabolite of clarithromycin is hiologic.;~lly itctive, in oitn, s~lsceptihility test was not availahle for this strldy
The primary rnd points of the efficacy :tn;tlysis in this study wrre clinical, radiologic. and hacteriologic responses.
(;linical response was hasrd on the c'r)mparison of clinical signs and symptoms hefore and after treatment. It was e v a l~~;~t e d independent of the 1,acteriologic findings. Fo~lr typrs ofclinical response cw~~ld he assigned: cure (resol~ltion of ;dl signs and s!mptoms); improvement (partial resol~ltion): failr~rr (no impro\.rmrnt): or relapse (deterioration ohserved at the first postther:~py visit after initial improvement). Similarly, radiologic response H~;IS graded as resol~~tion, improvement. r~nchanged, or worsening.
Three types of bacteriologic responses wrre possil)le. B;~cterio-logic ellre was defined :IS ahsence of the pretreatment pathogen in the posttreidment c111t11re. F;til~lre was defined as persistence of the pretreatment pathogen in the posttre:itment c~llt~lre. In ctlses of mixed infections, a mixed response c~)~~l d he assigned if at Ieirst one of the pathogens persisted in the posttreatment c~llt~lre. Reinfection was defined as the presence of a pathogen in the posttreatment cr~lt~lre that was different from the pathogen identified previorisly in the pretreatment c~~l t r~r e .
Recurrence was defined as reappearance on the follow-up c11lt11re of a pathogen that was previo~~sly eradicated.
Safity Analysis
All patients who received at least one dose of medication (either clarithromycin or erythromycin) were i n c l~~d e d in the safety analysis. Adverse events were cwmpared hetween the two treatment gror~ps with respect to the incidence, type. and severity of the events.
The hvo treatment groups were cnmpared at haselinr with respect to sex, race, severity of infection, overall clinical conditions using Fisher's exact test (two-tailed), and to age, weight, treatment duration, and n~~m h e r of lower respiratory tract infections within last 24 months using one-way analysis of variance techniq~ies. Both efficacy and safety analysis hetween the two treatment groups were cnmpared hy using Fisher's exact test (two-tailed), and p values of 0.05 or less were c'rmsiderrd statistically significant.
Among the 268 patients enrolled in the study, 173 Ninety-five patients were excluded from the efficacy analysis ( Table 2 ). The main reason for exclusion was receiving less than the minimum required period of therapy.
Eficacy Analysis
Efficacy of the two medications was compared among the 173 evaluable patients with respect to clinical, radiologic, and bacteriologic responses after treatment using intention-to-treat analytical approach.
Clinical and Radiologic Responses: Ninety-two evaluable patients received clarithromycin. At posttreatment assessment, 89 had either clinical cure (57 patients) or improvement (32 patients). Among the 81 evaluable patients receiving erythromycin, 78 had clinical cure or improvement at posttreatment assessment (Table 3) .
Complete resolution of radiologic abnormalities was observed in 82 patients receiving clarithromycin and 69 patients receiving erythromycin. Radiologic improvement was reported in six and nine patients in each group, respectively (Table 3) . No statistically significant difference in the clinical and radiologic responses was observed between clarithromycin and erythromycin.
Bacteriologic Response: Among the 173 evaluable patients, 43 positive pretreatment cultures were obtained (Table 4 ). In the clarithromycin group, eradication occurred in 23 of the 26 isolates (88 percent).
There were three failures after treatment (one S pneumoniae, two H influenme). In the erythromycin group, eradication occurred in all 17 isolates. However, the difference in the eradication rate between the two groups was not statistically significant (p = 0.287). No recurrence was observed in either group.
There were 27 positive serologic tests among the 173 evaluable patients (16 clarithromycin, 11 erythromycin): 20 for M pneumoniae and 7 for C pneumoniae.
All together, 70 pathogens were identified among the 173 evaluable patients. Forty-three were identified by bacterial cultures, and 27 were identified by serologic studies. However, only 65 evaluable patients had bacteriologic or serologic confirmed pneumonia. The discrepancy is due to five patients with mixed infections. The types of pneumonia among these 65 patients were presented in Table 5 . Thirty-seven patients had bacterial pneumonia caused by one pathogen. Twenty-three patients had pneumonia caused by either M pneumoniae or C pneumoniae. Five patients had mixed infections. Two patients had either mixed bacterial pneumonia or mixed bacterial and atypical pneumonia; one had pneumonia caused by both M pneumoniae and C pneunoniue. No statistically significant difference in clinical success rate was observed among these patients, whether treated with erythromycin or clarithromycin (p value = 1.00). 
Safety Analysis
All 268 enrolled patients were included in the safety analysis (Table 6 ). Overall, 120 adverse events were reported, and the majority of these events were drug related (110 of 120, 91 percent).
The incidence of adverse events was compared between the two treatment groups. The number of adverse events in the erythromycin group (79 events, 59 percent) was significantly higher than in the clarithromycin group (41 events, 31 percent).
The gastrointestinal system (GI) was the major organ system involved, accounting for the majority of drug-related adverse events. Patients receiving erythromycin had a significantly greater number of GIrelated adverse events than patients receiving clarithromycin (70 vs 25). The most frequent complaints were diarrhea, abdominal pain, nausea and vomiting.
Most of the adverse events were mild to moderate in nature. No death was attributed to drug-related adverse events. However, significantly (p<0.001) more patients receiving erythromycin (of 37 patients, 27 percent withdrew from the study due to drug-related adverse events than patients receiving clarithromycin (6 patients, 5 percent).
Overall, there were no clinically significant changes in vital signs, hematologic and coagulation profiles, serum chemistry, or urinalysis between the two groups.
Unlike most of the studies on community-acquired the target population in this study were ambulatory patients. The demographic data among evaluable patients suggested that it is representative of the general population. Most patients were white. There is a wide distribution of age, ranging from 12 to 93 years old. Only a minority of patients have underlying pulmonary diseases (15 percent).
Efficacy analysis showed that the two macrolides were equally effective, at the given doses, for the treatment of community-acquired pneumonia. After 7 to 14 days of oral therapy, with either clarithromycin, 250 mg twice a day, or erythromycin stearate, 500 mg four times a day, essentially identical clinical and radiologic responses were achieved with either medication. In addition, no statistically significant difference in the bacteriologic eradication rate was found between the two macrolides. Both were equally effective against S pneumoniae and H influenzae.
In oitm studies showed that the two macrolides were equipotent against M pneumoniae (MIC90 0.008 m&). However, clarithromycin is much more potent than erythromycin against C pneumoniae (MIC90 0.03 vs 0.125). Results in this study with a relatively small number of patients with serologically proven atypical pneumonia showed that both macrolides were equally successful in treating Mycoplasma as well as Chlamydia pneumonia. Clinical response was observed in all but one case of atypical pneumonia with either medication. A clinical study by Cassell et all3 also demonstrated the efficacy of clarithromycin against M ycoplasma pneumonia.
he two macrolides, however, differed significantly with respect to the number and severity of adverse events. At the doses used, the number of adverse events was two times higher among patients receiving erythromycin stearate than patients receiving clarithromycin (p<0.001), and withdrawal from the study was five times more frequent with erythromycin.
Our results lend support to those reported by Anderson et al.14 Their study also demonstrated that clarithromycin and erythromycin had comparable clinical success rates (over 90 percent) among patients with community-acquired pneumonia. In addition, patients receiving erythromycin had a higher incidence of adverse events and were more likely to withdraw from the study due to drug-related adverse events than those receiving clarithromycin. In their study, the most common pathogen was H influenzae, which supports the efficacy of clarithromycin against H influenzae.
Efficacy of clarithromycin against Legionella pneumophila was not assessed in the present study. A recent study by Hamedani et all5 showed that a clinical cure rate of 98 percent was achieved in 46 patients with Legionella pneumonia treated with oral clarithromycin, at a dose of 500 mg twice a day.
In conclusion, both orally administered clarithromycin and erythromycin stearate are effective against common pathogens responsible for community-acquired pneumonia. However, clarithromycin is associated with a lower incidence of drug-related GI side effects resulting in better compliance. Thus, oral clarithromycin may play an important role in the future outpatient management of lower respiratory tract infection. 
